retatrutide clinical trial data Retatrutide Clinical Trial – My Endo Consult

First Retatrutide phase 3 data, a Triumph of Science!

21.00

★★★★☆4.8 (126)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism

26.34

★★★★★4.9 (98)

Reta clinical trial data & dosing — a must read Retatrutide (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP,

26.30

★★★★★5.0 (157)

Retatrutide Results: How Much Weight Can You Lose & How Quick?

28.09

★★★★★4.7 (84)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

28.63

★★★★★4.9 (203)

Everyone's talking about Retatrutide… but what does the actual data say? Here's a breakdown based on published clinical trials: • 24.2% body weight loss (48 weeks) • 86% liver fat reduction (small

21.35

★★★★★5.0 (176)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

28.59

★★★★★4.8 (132)